Invasive Pulmonary Aspergillosis and Severe Influenza

Completed

• Conditions: Influenza; Aspergillosis; Critical Illness

• Registration Number: NCT04232956
• Lead Sponsor: University Hospital, Brest

Brief Summary

Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients with influenza infection with a highly variable incidence between 1 to 21%. Studies investigating IPA in critically ill patients with influenza infection suffer limitations in their methods. It remains unknown whether patients with influenza are more at risk of IPA than other patients hospitalized in intensive care unit and whether patients with influenza who develop IPA have specific risk factors for this infection.

Our study aims to determine the incidence of IPA in a large multicenter cohort and to identify risk factors for IPA in these patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-07-10
• Study Start: 2018-07-27
• Primary Completion: 2018-11-05
• Study Completion: 2018-11-05
• Status Verified: 2020-01
• Study First Submitted QC: 2020-01-15
• Last Update Submitted: 2020-01-15
• Study First Posted: 2020-01-18
• Last Update Posted: 2020-01-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 478

Inclusion Criteria

• Infection with influenza A or B
• Admission to one of the participating sites

Exclusion Criteria

• age < 18
• patients with invasive pulmonary aspergillosis prior to intensive care admission
• consent withdraw

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Invasive Pulmonary Aspergillosis	up to 100 days	incidence of invasive pulmonary aspergillosis

Trial Locations

Locations (4)

CHRU de Brest; 🇫🇷 Brest, France

CHR; 🇫🇷 Morlaix, France

CHU de NANTES; 🇫🇷 Nantes, France

CHU de Rennes; 🇫🇷 Rennes, France